Analysed AKESO INC (AKESF:OTCMKTS) News Sources
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
03-06-2026
pharmaceutical-technology.com
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
04-06-2026
pharmavoice.com
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
12-06-2026
yahoo.com
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
15-06-2026
yahoo.com
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
17-06-2026
yahoo.com
What is the current price of AKESO INC (AKESF:OTCMKTS)?
The current price of AKESO INC (AKESF:OTCMKTS) is $12.6525.
AKESO INC (AKESF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of AKESO INC (AKESF:OTCMKTS) since the previous trading day is $0.1525.
AKESO INC (AKESF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of AKESO INC (AKESF:OTCMKTS) since the previous trading day is 1.22%.
What is the most recent average sentiment score for AKESO INC (AKESF:OTCMKTS)?
The most recent average sentiment score for AKESO INC (AKESF:OTCMKTS) is 69 out of 100.
What is the most recent average sentiment for AKESO INC (AKESF:OTCMKTS)?
The most recent sentiment for AKESO INC (AKESF:OTCMKTS) is .
SEC-8K** Filing Available For AKESO INC (AKESF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.